复方台乌片治疗慢性萎缩性胃炎肝胃不和证的临床研究

发布时间：2018-11-24 12:57

【摘要】：目的:观察复方台乌片治疗慢性萎缩性胃炎肝胃不和证的临床疗效,并探讨其可能的作用机制,为临床治疗慢性萎缩性胃炎肝胃不和证提供有效的药物。方法:选择符合病例纳入标准的慢性萎缩性胃炎肝胃不和证门诊及住院患者53例,随机的分为治疗组和对照组,治疗组26例,对照组27例。治疗组给予复方台乌片治疗,每次5片,每日3次;对照组给予摩罗丹治疗,每次8丸,每日3次;合并幽门螺杆菌感染时同时给予抗幽门螺杆菌治疗。连续服药12周为一个疗程,共观察两个疗程。评价治疗效果及药物不良反应。结果:1.临床症状:对临床症状改善有效率,复方台乌片组为88.46%,摩罗丹组为81.48%,两组比较差异有统计学意义(P0.05)。2.胃镜:对胃镜下黏膜改善有效率,复方台乌片组为84.62%,摩罗丹组为77.78%,两组比较差异有统计学意义(P0.05)。3.病理:对胃黏膜慢性炎症改善有效率,复方台乌片组为76.92%,摩罗丹组为70.37%,两组比较差异有统计学意义(P0.05);对胃黏膜萎缩改善有效率,复方台乌片组为34.62%,摩罗丹组为37.04%,两组比较差异无统计学意义(P0.05);对胃黏膜肠化改善有效率,复方台乌片组为15.38%,摩罗丹组为22.22%,两组比较差异无统计学意义(P0.05);对胃黏膜异型增生改善有效率,复方台乌片组为7.69%,摩罗丹组为11.11%,两组比较差异无统计学意义(P0.05)。4.中医症候:对中医症候改善有效率,复方台乌片组为92.31%,摩罗丹组为85.19%,两组比较差异有统计学意义(P0.05)。5.中医症候积分:对中医症候积分改善有效率,复方台乌片组中胃脘痞满、胃脘胀痛、胁肋胀痛、口干、食少单项症候积分改善均优于摩罗丹组,两组比较差异有统计学意义(P0.05),余单项症候积分的比较差异无统计学意义(P0.05)。6.幽门螺杆菌根除情况:对Hp根除有效率,复方台乌片组为75%,摩罗丹组为73.68%,两组比较差异无统计学意义(P0.05)。7.两组治疗期间均未发现明显的不良反应。结论:1.复方台乌片在改善临床症状、胃镜下胃黏膜表现、胃黏膜慢性炎症及中医症候要优于摩罗丹。2.复方台乌片在改善胃脘痞满、胃脘胀痛、胁肋胀痛、口干、食少方面要优于摩罗丹。3.复方台乌片在改善腺体萎缩、肠上皮化生、异型增生及根除Hp方面与摩罗丹疗效相当。4.复方台乌片为临床安全、有效药物,值得进一步推广。
[Abstract]:Objective: to observe the clinical effect of compound Taiwu tablet in the treatment of chronic atrophic gastritis with liver and stomach disharmony, and to explore its possible mechanism so as to provide effective medicine for clinical treatment of chronic atrophic gastritis with liver and stomach disharmony. Methods: 53 patients with chronic atrophic gastritis were randomly divided into treatment group (n = 26) and control group (n = 27). The treatment group was treated with compound Tiewu tablet, 5 tablets per day, 3 times a day; the control group was treated with 8 pills, 3 times a day; and the patients with Helicobacter pylori infection were treated with anti-Helicobacter pylori at the same time. A course of treatment was taken for 12 weeks, and two courses of treatment were observed. To evaluate the therapeutic effect and adverse drug reactions. Results: 1. Clinical symptoms: the effective rate of improving clinical symptoms was 88.46 in compound Taiwu tablet group and 81.48 in Moro Dan group. The difference between the two groups was statistically significant (P0.05). Gastroscope: the effective rate of mucosal improvement under gastroscope was 84.62 in compound Taiwu tablet group and 77.78 in Moro Dan group. The difference between the two groups was statistically significant (P0.05). Pathology: the effective rate of improving chronic inflammation of gastric mucosa was 76.92in the compound Taiwu tablet group and 70.37in the Moro Dan group. The difference between the two groups was statistically significant (P0.05). The effective rate of improving gastric mucosal atrophy was 34.62 in compound Taiwu tablet group and 37.04am in Moro Dan group. There was no significant difference between the two groups (P0.05). The effective rate of improving intestinal metaplasia of gastric mucosa was 15.38 in compound Taiwu tablet group and 22.22 in Moro Dan group. There was no significant difference between the two groups (P0.05). The effective rate of improving gastric mucosal dysplasia was 7.69g in compound Taiwu tablet group and 11.11m in Moro Dan group. There was no significant difference between the two groups (P0.05). TCM symptoms: improve the effective rate of TCM symptoms, compound Taiwu tablet group is 92.31, Moro Dan group is 85.19, the difference between the two groups was statistically significant (P0.05). TCM symptom integral: improve the effective rate of TCM symptom integral, compound Taiwu tablet group is superior to Moro Dan group in improving the integral of stomachache, stomach distended pain, hypochondria pain, dry mouth and less food single symptom. The difference between the two groups was statistically significant (P0.05), while there was no significant difference between the remaining single symptom score (P0.05). The eradication rate of Helicobacter pylori: the effective rate of Hp eradication was 75 in the compound Tiewu tablet group and 73.68 in the Moro Dan group. There was no significant difference between the two groups (P0.05). No significant adverse reactions were found during treatment in both groups. Conclusion: 1. Compound Taiwu tablet is superior to Moro Dan in improving clinical symptoms, gastric mucosal manifestations, chronic inflammation of gastric mucosa and symptoms of traditional Chinese medicine. Compound Taiwu tablet is superior to Moro Dan in improving epigastric fullness, stomachache, flank pain, dry mouth and little food. The curative effect of Fufang Taiwu tablet on improving gland atrophy, intestinal metaplasia, dysplasia and Hp eradication was equivalent to that of Moro Dan. 4. 4. Compound Taiwu tablet is a safe and effective drug in clinic, and it is worth further popularizing.
【学位授予单位】：广西中医药大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R259

【参考文献】